These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22931248)

  • 21. Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
    Gordon AN; Asmar L; Messing MJ; Street DG; Pippitt CH; Bailey CL; Savage J; Young JA
    Gynecol Oncol; 2004 Aug; 94(2):533-9. PubMed ID: 15297200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.
    Hoskins PJ
    J Clin Oncol; 2009 Mar; 27(9):1355-8. PubMed ID: 19224837
    [No Abstract]   [Full Text] [Related]  

  • 23. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
    Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
    Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
    Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
    Pitakkarnkul S; Tangjitgamol S; Srijaipracharoen S; Manusirivithaya S; Pataradool K; Prutthiphongsit W; Khunnarong J; Thavaramara T
    Asian Pac J Cancer Prev; 2013; 14(4):2421-7. PubMed ID: 23725151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
    Villella J; Marchetti D; Odunsi K; Rodabaugh K; Driscoll DL; Lele S
    Gynecol Oncol; 2004 Dec; 95(3):539-45. PubMed ID: 15581960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
    Oza AM; Matulonis UA; Alvarez Secord A; Nemunaitis J; Roman LD; Blagden SP; Banerjee S; McGuire WP; Ghamande S; Birrer MJ; Fleming GF; Markham MJ; Hirte HW; Provencher DM; Basu B; Kristeleit R; Armstrong DK; Schwartz B; Braly P; Hall GD; Nephew KP; Jueliger S; Oganesian A; Naim S; Hao Y; Keer H; Azab M; Matei D
    Clin Cancer Res; 2020 Mar; 26(5):1009-1016. PubMed ID: 31831561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer].
    Ito K; Adachi S; Iijima T; Nakatsuji Y; Kimura T; Nobunaga T
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):141-4. PubMed ID: 12557720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Application of ATP-tumor chemosensitivity assay in primary epithelial ovarian cancer].
    Zhao D; Wu LY; Wang XB; Li XG; Li M; Li YF; Tian HM; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):368-72. PubMed ID: 20723436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
    Erriquez J; Olivero M; Mittica G; Scalzo MS; Vaira M; De Simone M; Ponzone R; Katsaros D; Aglietta M; Calogero R; Di Renzo MF; Valabrega G
    Oncotarget; 2016 May; 7(18):26181-91. PubMed ID: 27027433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
    Zhao D; Wu LY; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):855-8. PubMed ID: 21223693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent ovarian cancer: how important is it to treat to disease progression?
    Herzog TJ
    Clin Cancer Res; 2004 Nov; 10(22):7439-49. PubMed ID: 15569973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of advanced ovarian cancer.
    du Bois A
    Eur J Cancer; 2001 Dec; 37 Suppl 9():S1-7. PubMed ID: 11741767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
    Fransson Å; Glaessgen D; Alfredsson J; Wiman KG; Bajalica-Lagercrantz S; Mohell N
    J Ovarian Res; 2016 May; 9(1):27. PubMed ID: 27179933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103).
    Lindemann K; Beale PJ; Rossi E; Goh JC; Vaughan MM; Tenney ME; Martyn JK; Sommeijer D; Iglesias JL; Kremmidiotis G; Simpson J; Doolin E; Lavranos TC; Leske A; Veillard AS; Espinoza D; Stockler MR; Rischin D;
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):97-105. PubMed ID: 30368585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
    Zhao XD; Zhang Y; He SR; Yang L
    Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
    Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
    Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.